We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

47 hedge funds and large institutions have $409M invested in Stoke Therapeutics in 2019 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

45.24% more ownership

Funds ownership: 0% → 45.24% (+45%)

Holders
47
Holders Change
+47
Holders Change %
–
% of All Funds
1.02%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
47
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$90.1M
2
CAM
Cormorant Asset Management
Massachusetts
+$50.2M
3
GGHC
Gilder Gagnon Howe & Co
New York
+$50M
4
RCM
RA Capital Management
Massachusetts
+$30.1M
5
RG
Redmile Group
California
+$27.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$92.6M +$90.1M +3,355,466 New
CAM
2
Cormorant Asset Management
Massachusetts
$54.5M +$50.2M +1,869,680 New
GGHC
3
Gilder Gagnon Howe & Co
New York
$54.3M +$50M +1,861,623 New
RCM
4
RA Capital Management
Massachusetts
$32.7M +$30.1M +1,119,963 New
RG
5
Redmile Group
California
$29.8M +$27.4M +1,021,808 New
PA
6
Perceptive Advisors
New York
$19.6M +$18M +671,978 New
Fidelity Investments
7
Fidelity Investments
Massachusetts
$19M +$17.5M +650,000 New
Millennium Management
8
Millennium Management
New York
$16.1M +$14.8M +552,730 New
Wellington Management Group
9
Wellington Management Group
Massachusetts
$11.9M +$10.9M +406,471 New
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$11.7M +$10.7M +400,000 New
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$11M +$10.1M +376,900 New
SFM
12
Sphera Funds Management
Israel
$9.72M +$9.42M +350,944 New
AI
13
Atom Investors
Texas
$5.82M +$5.36M +199,513 New
OAM
14
Oxford Asset Management
United Kingdom
$5.33M +$4.91M +182,671 New
O
15
OrbiMed
New York
$3.79M +$3.49M +130,000 New
Federated Hermes
16
Federated Hermes
Pennsylvania
$3.35M +$3.09M +115,000 New
American Century Companies
17
American Century Companies
Missouri
$3.06M +$2.82M +104,883 New
Vanguard Group
18
Vanguard Group
Pennsylvania
$2.92M +$2.69M +100,000 New
Citadel Advisors
19
Citadel Advisors
Florida
$2.91M +$2.68M +99,818 New
CC
20
Casdin Capital
New York
$2.48M +$2.28M +85,000 New
Goldman Sachs
21
Goldman Sachs
New York
$2.32M +$2.14M +79,662 New
MIM
22
Monashee Investment Management
Massachusetts
$2.18M +$2M +74,621 New
Alyeska Investment Group
23
Alyeska Investment Group
Illinois
$1.46M +$1.35M +50,167 New
BlackRock
24
BlackRock
New York
$1.33M +$1.23M +45,651 New
DKCM
25
Davidson Kempner Capital Management
New York
$1.17M +$1.07M +40,000 New
1
2

STOK Hedge Fund Activity: Q2 2019 in Review

47 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2019, worth a combined $409M.

Buyers outnumbered sellers: 47 funds opened new STOK positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $90.1M.

  • 47 institutional investors held Stoke Therapeutics (STOK) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $409M of Stoke Therapeutics stock for Q2 2019.
  • 47 funds opened new Stoke Therapeutics positions in Q2 2019 and 0 closed out, a net change of +47 holders.
  • The largest Stoke Therapeutics buyer in Q2 2019 was RTW Investments, an estimated $90.1M added.

Based on aggregated 13F filings for Q2 2019.